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Abstract 
 
Background:  Post-transplant non-melanoma skin cancers (NMSC) are the most common 
malignancies in kidney transplant recipients.  
Objective: To analyse risk factors associated with the occurrence of basal cell carcinomas 
(BBC) and squamous cell carcinomas (SCC). 
Patients and Methods: Statistical analysis was performed on 376 kidney transplant 
recipients screened NMSC in the years 2002-2009 and followed-up until 2013.  
Results: NMSC developed in 23.67% of individuals with an SCC/BCC ratio of 2.15 : 1 and an 
age-standardized incidence ratio (IR) of 2.71 cases (95% CI, 1.97 - 3.46) per 100 
patients/year. In multivariable analysis NMSC occurrence significantly correlated with higher 
age (p<0.001), fair skin type (p = 0.01) and particularly in SCCs with male gender (p = 0.001). 
Patients with >10 AKs were at higher risk to develop NMSCs (IRR = 2.95; 95% CI, 1.97 – 4.42; 
p < 0.001) and more prone to SCCs as compared to BCCs (p = 0.04). Also, more SCC carriers 
had high counts of warty lesions (p = 0.006). Calcineurin-inhibitors were associated with 
higher NMSC incidence (IRR = 2.81; 95% CI, 1.13 - 7.01; p = 0.03), while no difference was 
seen with mammalian target of Rapamycin (mTOR)-inhibitors.   
Conclusions:  In addition to the duration of immunosuppression our results further confirm 
an influence of the individual immunosuppressive regimen and suggest that older patients, 
males, fair skinned recipients or those affected with high AK counts (field cancerization) are 
particularly prone to NMSC development. 
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Introduction 
Non-melanoma skin cancer (NMSC) is the most common type of neoplasm in humans and 
also the malignant disease that is increasingly prevalent among organ transplant recipients 
(OTRs) due to long-term immunosuppressive therapy and other factors 1.  Tumours can be 
more aggressive in OTRs than in the general population with a rapid progression and 
destructive behaviour, resulting in significantly higher morbidity and mortality 2. In contrast 
to the immunocompetent population, skin cancers in OTRs are dominated by squamous cell 
carcinoma (SCC), followed by basal cell carcinoma (BCC). In fact, transplanted individuals of 
Caucasian Origin have a 60-to 250-fold increased risk for SCC and a 10-fold increased risk for 
BCC, while for malignant melanoma the incidence appears only 2-3 folds higher than in the 
general population 3, 4. SSCs develop predominantly in areas of field cancerization with 
multiple actinic keratosis (AK) or Bowen disease and their risk of metastases is increased to 
approximately 8% for OTRs as compared to 0.5% - 5% in the general population 5. Moreover, 
SCCs and BCCs do occur earlier in OTRs as compared to immunocompetent controls and 
apparently their cumulative incidence rises linearly without a delay after transplantation 
with a decreasing time interval for subsequent tumours 6. 
Apart from immunosuppression other potential co-factors contributing to the augmented 
likelihood for evolving NMSCs in this patient group have to be considered. Among better 
defined co-stimuli, indicative of an increased NMSC risk in OTRs patients, there are 
ultraviolet radiation exposure, male sex, fair skin, presence of keratotic skin lesions, age at 
transplant or duration and extent of the immunosuppression therapy 7, 8. In addition, the 
choice of immunosuppressive agents may be relevant to explain an augmented risk in these 
patients 9.  
After an initial report from a previous multivariable analysis in 243 renal transplant patients, 
seen by our group until 2005 10, the purpose of this study was to further extent and validate 
the parameters determining the occurrence of SCCs and BCCs in our retrospective cohort of 
376 kidney transplant recipient and to better define the potential impact of 
immunosuppressive drugs administered to these patients.  
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Materials and Methods 
Patient cohort 
Data from 376 patients who underwent renal transplantation between May 1970 and 
January 2009 were retrospectively collected and follow-up examinations reported until end 
of 2013. Starting as of 2002 all patients were examined at our special dermatological 
consultation unit at the department of nephrology in accordance with internal guidelines of 
the University of Bern and screened for the occurrence of new NMSC and respective 
premalignant lesions. The study was approved by the local ethical committee and all 
patients gave written informed consent.  Prior to kidney transplantation all patients had 
been checked by a dermatologist for skin cancers and/or premalignant conditions and 
treated for evident lesions. 
Apart from patient specific characteristics at study entrance (Age, sex, skin type, duration of 
immunosuppression, type of immunosuppression) the following parameters were 
documented and followed in addition at each visit: all clinically evident skin lesions suspect 
for actinic keratosis (AK), SCC or BCC, as well as the type and dosage of immunosuppression. 
If a lesion was clinically clearly recognised as AK, treatment was performed without 
histological confirmation. In all other cases a punch biopsy was evaluated histologically.    
 
Statistical Analysis 
For descriptive purpose data are presented as means and standard deviations (SD) or 
numbers with percentages for continuous and categorical variables respectively. Incidence 
of first NMSC was computed as incidence rate (IR) per 100 patients/year, together with its 
95% confidence interval (CI), by assuming a Poisson distribution. Age-standardized IR was 
calculated by taking the age structure of the 2000 EU population as reference. For graphical 
purpose cumulative incidence rates were computed by means of Kaplan-Meier estimator. 
Pearson’s χ2 test was used to test for difference between categorical variables. 
Multiple Poisson regression analysis, including terms for age and gender, was used to assess 
which factors influenced the incidence of first NMSC in the first 20 years of 
immunosuppression. Effects of selected factors were expressed as incidence rates ratios 
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(IRR) along with their 95% CI and p-value. Robust standard errors of parameter estimates 
were computed to control for mild violation of equal mean and variance assumption. This 
was also tested by considering a ratio of the deviance and the degree of freedom of its 
distribution lower than 1. A continuity correction was applied to univariate Poisson model in 
case of zero entries in one stratum. Analyses were carried out with SPSS ver. 20 (IBM Corp). 
All tests were considered significant at p-value <0.05. 
 
Results 
Patient characteristics are summarized in table 1. The mean age of patients at 
transplantation was 44.1 ± 14.6 years (mean ± SD), with a male : female ratio of 1.63 : 1. 
Most of them had a skin type of I or II (54.0%) according to Fitzpatrick types I-VI. Overall the 
number of AK lesions at study entry was between 1 - 10 for 39.2% of patients and over 10 
for 6.9% of them. The mean immunosuppressive treatment duration was 10.6 ± 7.4 years 
including all follow-up visits (mean number of consultations 3.54 ± 3.43).  A mean number of 
2.54 ± 0.6 immunosuppressive drugs were combined in 22 different regimens. Overall the 
most prescribed treatments were prednisone (89.3%) and cyclosporine (81.9%), followed by 
MMF (35.5%) and azathioprine (32.0%). 
Among our 233 male and 143 female renal transplant recipients a total of 89 individuals 
(23.67%) developed at least one NMSC (Figure 1a). The mean duration until the detection of 
the first skin cancer was 12.56 ± 7.6 years. The age-standardized IR was 2.71 cases (95% CI, 
1.97 - 3.46) per 100 patients/year for NMSC, 1.76 cases (95% CI, 1.19 - 2.33) for BCC and 1.76 
cases (95% CI, 1.17 - 2.36) for SCC (Table 2). Overall 358 NMSCs (249 SCCs, 109 BCCs) were 
observed since first visit corresponding to an average of 4.0 skin cancers per tumour patient. 
30 Patients (8.0% from study group or 33.7% from the tumour bearing subgroup) had both 
SCCs and BBCs, while 27 (7.2 / 30.3 %) had only SCCs and another 32 individuals were 
recorded with BCCs only (8.5 / 35.9 %).  The SCC/BCC ratio was 2.15 : 1 in our series.  
According to multivariable analysis in the first 20-years of immunosuppression (Table 3), 
males were more likely than females to develop a NMSC (IRR = 1.74; 95% CI, 1.11 - 2.73) and 
in particular a SCC (IRR = 3.30; 95% CI, 1.64 - 6.64). Age had also a significant impact on 
NMSC incidence, with a clear trend towards higher age groups (Figure 1b). Patients with >10 
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AKs (defined as field cancerisation) were at higher risk to develop NMSCs (IRR = 2.95; 95% CI, 
1.97 – 4.42; p < 0.001). For SCCs the IRR was 5.58 (95% CI, 3.30 – 9.44; p < 0.001) and for 
BCCs 2.51 (95% CI, 1.47 – 4.29; p = 0.001). The risk for SCCs was higher as compared to the 
occurrence of BCCs (p = 0.04). Correspondingly, in SCC carriers significantly more individuals 
had associated high counts of warty lesions (61.4%) as compared to patients with only BCCs 
(31.2%) (p = 0.006). A skin type of I-II was linked with an increased risk of NMSC (IRR = 1.82; 
95% CI, 1.13 - 2.94) and in particular of BCC (IRR = 2.34; 95% CI; 1.23 - 4.45). Among the 
prescribed drugs, only cyclosporine/tacrolimus showed an association with NMSC incidence 
(IRR = 2.81; 95% CI, 1.13 - 7.01), while in our patients there was no significant impact with 
the introduction of sirolimus/everolimus (p = 0.10). Figures 2 a and b display the influence of 
different medications on the cumulative incidence rates of NMSC since transplantation. 
 
Discussion 
Considering the success rates in kidney grafting together with an ongoing demand, we are 
facing a steadily increasing number of long-term renal transplant survivors. Given the high 
incidence and aggressive biologic behaviour of NMSC in affected recipients, early detection 
and removal of NMSCs and respective precursor lesions has become a major challenge. The 
group screened for skin cancer in this study was predominantly composed of male recipients 
and our data confirmed an increased risk for developing mainly SCCs. This gender difference 
reflects data frequently reported by other studies with less females being affected by end-
stage renal disease, while in some countries a still persisting gender discrimination in 
benefiting from medical treatment might explain a more pronounced impact 11. The 
association of male gender with a higher incidence of potentially metastatic SCCs makes 
male kidney recipients an even more sensitive target group for education efforts, regular 
skin examinations and preventive measures.  
Epidemiological studies have demonstrated NMSCs to be the most common malignancies 
arising after organ transplantation in Caucasians 12 and a recent Swedish population based 
investigation confirmed these results, with the bulk of the excess hazard driven by an 
exceptionally high and accelerating risk of SCC 13.  Our current data, with 23.67% of patients 
developing NMSCs after a mean of 12.56 ± 7.6 years post-transplantation are in accordance 
with those reported from other cohort studies. Indeed, the incidence of NMSC in the US- 
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and western European recipient population increases from 10% to 27% at 10 years and from 
40% to 60% at 20 years post-transplant, compared to the highest incidence reported in 
Australia, which is even 80% at 20 years 5. In contrast, latest data from Korean and Chinese 
transplant centres further approved a dissimilar malignancy pattern in Asian organ 
recipients. Whereas the risk of several cancer types is higher than that in the general 
population, even in long-term follow-ups the cumulative incidence of post-transplantation 
skin cancer remains extremely low as compared to populations from western countries 14,15. 
Consequently, the burden of NMSCs contributes to a substantial morbidity in OTRs of 
Caucasian origin.  In a retrospective analysis of the Irish Renal Transplant Database of 255 
patients with ultra-long-term (>20 year) renal allograft survival skin cancer was by far the 
leading comorbidity (36.1%), followed by coronary heart disease (17.3%) and other 
malignancies (14.5%) 16.  Accordingly, NMSCs add to a substantial economic load of health 
care costs in renal graft recipients and may even be responsible for post-transplant 
mortality17.  At least, in Australian liver and cardiothoracic transplant recipients de novo 
cancer was a leading cause of late death, with the highest relative risk due to NMSC 18.  
Thus, apart from screening awareness and a close collaboration of renal transplant teams 
and dermatologists, in particular photo-protection, skin self-examination or a change in 
immunotherapy were suggested as effective measures against NMSC development in such 
patients 19.  Primarily, a preventive and aggressive treatment of actinic keratosis in areas of 
field cancerization is recommended to cut down on the high morbidity and avoid the 
mortality associated with invasive squamous cell carcinoma in OTRs 2.  
Also a conversion of immunosuppressive drugs to m-TOR-inhibitors has been demonstrated 
to reduce the development of new AKs and NMSCs in several studies as reviewed in a recent 
meta-analysis in 5876 subjects from 21 randomized trials 20. According to Karayannopoulou 
and coworkers the considerably higher expression of phospho-mTOR in SCCs compared to -
BCCs might explain their higher sensitivity to mTOR-inhibitors 21. In our study, among 33 
patients (7.95%) receiving sirolimus on 1st visit only two subjects developed BCCs while no 
SCC could be observed. Yet, no difference could be demonstrated as compared to patients 
without mTOR-inhibitors probably due to a lack of power in our cohort.  
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In summary, our current data suggest older patients, males, fair skinned recipients,   those 
presenting multiple warty lesions or field cancerisation to be a particular high-risk group for 
NMSCs among renal transplant recipients that should probably benefit best from a close 
follow-up and active surveillance. 
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Tables and Figures 
 
 
Table 1 Characteristics of 376 renal transplanted patients included in the study 
 N*=376 % Mean SD 
Gender Male 233 62.0%   
Female 143 38.0%   
Age at transplantation (years)   44.1 14.6 
Skin Type I - II 157 54.0%   
III 114 39.2%   
IV - VI 20 6.9%   
Number of AK lesions  0 246 66.0%   
1 - 10 83 22.3%   
>10 44 11.8%   
Age at first visit (years)    51.2 13.2 
Number of visits    3.5 3.4 
Follow-up (years)    10.6 7.4 
Immunosuppressant Drugs Prednisone 335 89.3%   
Cyclosporine 307 81.9%   
MMF 133 35.5%   
Azathioprin 120 32.0%   
Tacrolimus 21 5.6%   
Sirolimus/Everolimus 33 8.8%   
Number of combined drugs   2.5 0.6 
SD = standard deviation, AK: actinic keratosis 
* Numbers may not add up to the total due to missing data 
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Table 2 - NMSC incidence rates x 100 patients/year, overall and by age groups 
 N* Patients/year IR (95% CI) Age standardized IR (95% CI) 
NMSC 89 3672.58 2.42 (1.92 - 2.93) 2.71 (1.97 - 3.46) 
  Age<35 19 1411.68 1.32 (0.73 - 1.91)  
  Age 35-49 34 1333.38 2.55 (1.69 - 3.41)  
  Age 50+ 35 927.52 3.77 (2.52 - 5.02)  
BCC 62 3764.83 1.65 (1.24 - 2.06) 1.76 (1.19 - 2.33) 
  Age<35 15 1431.27 1.05 (0.52 - 1.58)  
  Age 35-49 21 1375.00 1.53 (0.87 - 2.18)  
  Age 50+ 25 958.56 2.61 (1.59 - 3.63)  
SCC 57 3775.83 1.51 (1.12 - 1.90) 1.76 (1.17 - 2.36) 
  Age<35 10 1435.90 0.70 (0.26 - 1.13)  
  Age 35-49 24 1364.04 1.76 (1.06 - 2.46)  
  Age 50+ 23 975.89 2.36 (1.39 - 3.32)  
N = number of cases, CI = confidence interval, IR = incidence rate 
* Numbers may not add up to the total due to missing data 
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Table 3   Multivariable analysis of factors influencing NMSC incidence rates during the first 
20 years of immunosuppression 
 NMSC BCC SCC 
 IRR (95% CI)* p-value IRR (95% CI)* p-value IRR (95% CI)* p-value 
Gender       
  Male 1.74 (1.11 - 2.73) 0.02 1.28 (0.75 - 2.21) 0.37 3.30 (1.64 - 6.64) 0.001 
  Female 1  1  1  
Age (yrs)       
  <35 1  1  1  
  35 – 49 2.53 (1.33 - 4.81) 0.005 1.73 (0.80 - 3.73) 0.17 6.56 (2.06 - 20.93) 0.001 
  50+ 4.70 (2.49 - 8.88) <0.001 3.73 (1.80 - 7.74) <0.001 11.25 (3.55 - 35.66) <0.001 
Skin type       
  I – II 1.82 (1.13 - 2.94) 0.01 2.34 (1.23 - 4.45) 0.01 1.58 (0.86 - 2.92) 0.14 
  III – VI 1  1  1  
Number of AK lesions       
 ≤ 10 1  1  1  
  >10 2.95 (1.97 - 4.42) <0.001 2.51 (1.47 - 4.29) 0.001 5.58 (3.30 - 9.44) <0.001 
Drugs       
Prednison       
  No 1  1  1  
  Yes 1.71 (0.79 - 3.68) 0.17 1.93 (0.63 - 5.85) 0.25 1.26 (0.52 - 3.04) 0.60 
Ciclosporin/Tacrolimus       
  No 1  1  1  
  Yes 2.81 (1.13 - 7.01) 0.03 2.39 (0.80 - 7.18) 0.12 1.64 (0.66 - 4.07) 0.29 
MMF       
  No 1  1  1  
  Yes 0.93 (0.56 - 1.53) 0.76 0.83 (0.43 - 1.61) 0.58 0.66 (0.32 - 1.36) 0.26 
Azathioprin       
  No 1  1  1  
  Yes 1.29 (0.85 - 1.96) 0.23 1.19 (0.69 - 2.07) 0.52 1.63 (0.95 - 2.78) 0.08 
Sirolimus/Everolimus       
  No 5.11 (0.71 - 36.63) 0.10 3.42 (0.48 - 24.47) 0.22 7.46 (0.70 - 79.63)^ 0.10 
  Yes 1  1  1  
IRR: incidence rate ratio, CI: confidence interval, AK: actinic keratosis 
*Estimates from Poisson regression models including terms for age and gender 
^ Estimate obtained by applying a continuity correction to univariate Poisson model 
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Figure 1 NMSC cumulative incidence rates since transplantation, overall (a) and by age 
groups (b) 
a) 
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b) 
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Figure 2 NMSC cumulative incidence rates in the first 20 years after transplantation, by use 
of Cyclosporine/Tacrolimus (a) and Sirolimus/Everolimus (b) 
a) 
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